70,781 Shares in GENMAB A/S/S $GMXAY Bought by Madison Asset Management LLC

Madison Asset Management LLC acquired a new position in shares of GENMAB A/S/S (OTCMKTS:GMXAY) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 70,781 shares of the company’s stock, valued at approximately $1,944,000.

GENMAB A/S/S Price Performance

Shares of GMXAY opened at $31.94 on Friday. GENMAB A/S/S has a twelve month low of $12.10 and a twelve month high of $19.00. The company’s fifty day simple moving average is $28.32 and its 200-day simple moving average is $27.92.

GENMAB A/S/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.

Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.